GET DAILY SIGNALSCodexis (CDXS) Delivers +124% Revenue Growth in Q3 With Stronger Margins
Key Takeaways
- Total revenue climbed roughly 124% year over year (YoY) to $19.3 million, led by product revenue of $15.7 million.
- Product gross margin improved to 74.5%, up from 64% in the same quarter a year earlier.
- Net loss narrowed to $8.1 million, or $0.08 per share, compared with a loss of $19.6 million, or $0.22 per share, a year ago.
- Results came in ahead of consensus expectations, and management reaffirmed full-year 2026 revenue guidance of $72 million to $76 million while raising its gross margin outlook to about 70%.
- The company ended the quarter with $72.7 million in cash, cash equivalents, and short-term investments, and closed a $60 million term loan after the quarter ended.
- For additional context, explore the Major News, Today's Price Move, Price Targets, and Forecast pages to learn more about Codexis (CDXS).
- You can also explore Trending AI Robots to discover AI-powered trading tools and ideas.
Putting the Quarter in Context
Codexis (CDXS) provides enzymatic solutions for manufacturing complex therapeutics. Its third-quarter results gave a clearer picture of whether the shift in product mix and tighter cost management are starting to pay off. After several periods of uneven revenue, the sharp year-over-year top-line increase suggests newer, higher-margin offerings are gaining traction. The quarter also matters because the company continues to invest in its ECO Synthesis platform for RNA-based medicines while still reporting a net loss. For investors, this report served as an important checkpoint on revenue growth, margin expansion, expense control, and balance-sheet strength heading into 2027.
Breaking Down the Reported Results
Codexis (CDXS) posted third-quarter 2026 total revenue of $19.3 million, up from $8.6 million a year earlier. Product revenue of $15.7 million drove most of the increase, while research and development revenue added $3.5 million. The top line edged ahead of consensus estimates near $18.7 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Product gross margin rose to 74.5% from 64% in the prior-year quarter, reflecting a shift toward higher-margin products. Operating expenses declined, with R&D spending at $12.6 million and SG&A expenses at $10.1 million, both below year-ago levels.
The company reported a net loss of $8.1 million, or $0.08 per share, narrower than the $19.6 million loss, or $0.22 per share, from a year earlier. The per-share result beat the consensus estimate of roughly $0.09 to $0.10. Management reaffirmed full-year 2026 revenue guidance of $72 million to $76 million and raised its gross margin outlook to approximately 70%. As of September 30, 2026, cash, cash equivalents, and short-term investments stood at $72.7 million. After the quarter, the company closed a $60 million senior secured term loan with Trinity Capital and drew $42.5 million at closing to refinance existing debt.
How the Market Reacted
Shares of Codexis (CDXS) rose in after-hours trading as investors reacted positively to the revenue beat, higher gross margin, and narrower loss. The response contrasted with the stock’s recent weakness, which included notable declines over the trailing three- and twelve-month periods.
Discussion around the report focused on the sustainability of product revenue growth, the ability to maintain margin expansion, and liquidity strength. While the ongoing net loss and cash burn remain points of attention, the reaffirmed revenue guidance and improved gross margin outlook were seen as positive signs that Codexis (CDXS) is advancing its move toward higher-value products and better cost discipline.
What to Watch Going Forward
Looking ahead, the focus will be on whether Codexis (CDXS) can sustain revenue momentum and margin gains through the fourth quarter and into next year. The reaffirmed 2026 revenue target of $72 million to $76 million implies a notable increase in fourth-quarter revenue. The raised gross margin outlook near 70% suggests management expects the favorable product mix to continue.
Further out, construction of the ECO GMP Manufacturing Center stands out as a key catalyst. Retrofit work is slated to begin early next year, with the facility expected to be operational by the end of 2027 to produce siRNA material for preclinical and clinical trials. Other items to monitor include progress on clinical-stage manufacturing agreements, expansion of CDMO partnerships, and ongoing development of the ECO Synthesis platform. Cash runway is also in view: after the equity raise and term loan, management has stated that existing resources should support operations through the end of 2028. Execution risk around scaling technology and converting pilot work into commercial contracts will remain central to the story.
Integrating AI Tools Into My Research Process
When reviewing companies like Codexis (CDXS), I often turn to Tickeron’s AI Screener to quickly filter for comparable names based on fundamentals, technical patterns, and performance metrics. It helps surface ideas aligned with specific strategies without spending hours on manual searches. The tool’s customizable filters make it straightforward to compare margin trends or revenue growth across the sector and stay organized while building a broader watchlist.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CDXS's Indicator enters downward trend
The Aroon Indicator for CDXS entered a downward trend on November 12, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 238 similar instances where the Aroon Indicator formed such a pattern. In 212 of the 238 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXS as a result. In 81 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CDXS turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CDXS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in 216 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CDXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.588) is normal, around the industry mean (3.498). P/E Ratio (-3.273) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.588) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. CDXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biocatalytic chemical processes
Industry Biotechnology
Advertisement